您当前的位置:
Antibody-Drug Conjugates (ADCs)

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. This antibody-based molecular platform enables selective delivery of a potent cytotoxic payload to target cancer cells, resulting in improved efficacy, reduced systemic toxicity, and preferable pharmacokinetics (PK)/pharmacodynamics (PD) and biodistribution compared to traditional chemotherapy.

All three component parts of an ADC, the antibody, the cytotoxic agent, and the linker that joins them, are critical elements in its design. The antibody moiety should be specific for a cell surface target molecule that is selectively expressed on cancer cells, or overexpressed on cancer cells relative to normal cells. The payload of an ADC must be highly cytotoxic so that it can kill tumor cells at the intracellular concentrations achievable following distribution of the ADC into solid tumor tissue, and because only a limited number of payloads can be linked to an antibody molecule (typically an average of 3-4 payloads per antibody) without severely compromising its biophysical and pharmacokinetic properties. The cytotoxic compounds include derivatives of calicheamicin, a class of highly cytotoxic enediyne antibiotics which kill cells by causing DNA double-strand breaks, and derivatives of the potent antimitotic microtubule-disrupting agents, dolastatin 10 (auristatins) and maytansine.

The third vital component of an ADC is the linker that forms a chemical connection between the payload and the antibody. The linker should be sufficiently stable in circulation to allow the payload to remain attached to the antibody while in circulation as it distributes into tissues (including solid tumor tissue), yet should allow efficient release of an active cell-killing agent once the ADC is taken up into the cancer cells. Linkers can be characterized as either cleavable, or as non-cleavable.

Antibody-Drug Conjugates (ADCs)(39)

Cat. No. Product Name CAS No. Purity Chemical Structure
KM32393 AGD-0182 1835700-14-5
KM37423 Anetumab ravtansine 1375258-01-7
KM37423 Anetumab ravtansine 1375258-01-7 99%
KM38162 ARC19499 1350667-54-7
KM38328 Azintuxizumab vedotin 1826819-58-2 98%
KM39016 Belantamab mafodotin 2050232-20-5 98%
KM32775 Cantuzumab ravtansine 868747-45-9 98%
KM36077 Cofetuzumab pelidotin 1869937-48-3 99%
KM38156 Danicamtiv-d3 2925925-82-0
KM38155 Danicamtiv-d6 1970975-54-2
KM38085 DBCO-PEG4-VA-PABC-MMAE 3049211-57-3 98%
KM31829 Enfortumab vedotin-ejfv 1346452-25-2 98%
KM36787 Farletuzumab ecteribulin 2407465-18-1 98%
KM35454 Givastomig 2762499-30-7 98%
KM39026 Ifinatamab deruxtecan 2484870-92-8 99%
KM37161 Ladiratuzumab vedotin 1629760-29-7
KM37161 Ladiratuzumab vedotin 1629760-29-7 99%
KM38892 Lifastuzumab vedotin 1401812-88-1 99%
KM36890 Lupartumab Amadotin 1640972-00-4 99%
KM32682 MASTL-IN-5 3024916-78-4